Alectinib and SALL4-Targeted Fatty Acid Oxidation: A Strategy to Combat Oxaliplatin Resistance in Gastric Cancer
This research has brought to light that Alectinib targets SALL4 to modulate the FAO process, thereby reducing the oxaliplatin resistance of GC cells. These findings may open up new avenues to tackle chemoresistance in GC.
Authors
- Jian Liao (ORCID: https://orcid.org/0000-0003-3519-4485)
- H Zhou
- Kaining Fang
- Yang Xiao (ORCID: https://orcid.org/0000-0001-8033-9909)
- Zheng Liu (ORCID: https://orcid.org/0000-0002-0240-2121)
- Hui Ouyang (ORCID: https://orcid.org/0000-0002-1246-879X)
- Ke Liu (ORCID: https://orcid.org/0000-0002-2903-8462)
- Weidong Zhu
Institutions
- Shanghai University of Traditional Chinese Medicine (CN)
- The First Hospital of Changsha (CN)
- Yueyang Second People's Hospital (CN)
- Yueyang Hospital (CN)
Publication Details
- Journal
- The Turkish Journal of Gastroenterology
- Published
- 2025-06-23
- DOI
- https://doi.org/10.5152/tjg.2025.24495
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00